JP2020505426A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505426A5 JP2020505426A5 JP2019541403A JP2019541403A JP2020505426A5 JP 2020505426 A5 JP2020505426 A5 JP 2020505426A5 JP 2019541403 A JP2019541403 A JP 2019541403A JP 2019541403 A JP2019541403 A JP 2019541403A JP 2020505426 A5 JP2020505426 A5 JP 2020505426A5
- Authority
- JP
- Japan
- Prior art keywords
- lung cancer
- item
- cell
- smarca2
- smarca4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 60
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims description 49
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims description 49
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims description 49
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 44
- 230000002062 proliferating effect Effects 0.000 claims description 44
- 201000005202 lung cancer Diseases 0.000 claims description 40
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 36
- 208000020816 lung neoplasm Diseases 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 210000004072 lung Anatomy 0.000 claims description 21
- 230000003902 lesion Effects 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000003623 enhancer Substances 0.000 claims description 10
- 230000008826 genomic mutation Effects 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 206010054949 Metaplasia Diseases 0.000 claims description 8
- 230000007705 epithelial mesenchymal transition Effects 0.000 claims description 8
- 230000015689 metaplastic ossification Effects 0.000 claims description 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 7
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 7
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 7
- 230000001747 exhibiting effect Effects 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000009956 adenocarcinoma Diseases 0.000 claims description 4
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims description 4
- 239000010425 asbestos Substances 0.000 claims description 4
- 208000019493 atypical carcinoid tumor Diseases 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 208000003849 large cell carcinoma Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052895 riebeckite Inorganic materials 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 208000000649 small cell carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 229950004774 tazemetostat Drugs 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims 2
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 101150046249 Havcr2 gene Proteins 0.000 description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 229940125563 LAG3 inhibitor Drugs 0.000 description 2
- 229940125568 MGD013 Drugs 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229940121569 ieramilimab Drugs 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- 0 CC(c1cc(C2=CCC(C*3CCCCC3)CC2)cc(*2)c1C(C)=*C2C1CCCC1)=O Chemical compound CC(c1cc(C2=CCC(C*3CCCCC3)CC2)cc(*2)c1C(C)=*C2C1CCCC1)=O 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022210528A JP2023026523A (ja) | 2017-02-02 | 2022-12-27 | 癌処置様式 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453929P | 2017-02-02 | 2017-02-02 | |
| US62/453,929 | 2017-02-02 | ||
| US201762479878P | 2017-03-31 | 2017-03-31 | |
| US62/479,878 | 2017-03-31 | ||
| PCT/US2018/016562 WO2018144798A1 (en) | 2017-02-02 | 2018-02-02 | Cancer treatment modalities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022210528A Division JP2023026523A (ja) | 2017-02-02 | 2022-12-27 | 癌処置様式 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505426A JP2020505426A (ja) | 2020-02-20 |
| JP2020505426A5 true JP2020505426A5 (enExample) | 2021-03-18 |
| JP7324144B2 JP7324144B2 (ja) | 2023-08-09 |
Family
ID=63041113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019541403A Active JP7324144B2 (ja) | 2017-02-02 | 2018-02-02 | 癌処置様式 |
| JP2022210528A Pending JP2023026523A (ja) | 2017-02-02 | 2022-12-27 | 癌処置様式 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022210528A Pending JP2023026523A (ja) | 2017-02-02 | 2022-12-27 | 癌処置様式 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190350929A1 (enExample) |
| EP (1) | EP3576729A4 (enExample) |
| JP (2) | JP7324144B2 (enExample) |
| CN (1) | CN110366413A (enExample) |
| AU (1) | AU2018217139A1 (enExample) |
| WO (1) | WO2018144798A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| MX376008B (es) | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| MX2018002344A (es) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Metodo para tratar el cancer. |
| CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤の使用 |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
| CN115666725A (zh) * | 2020-05-28 | 2023-01-31 | Epizyme股份有限公司 | Ezh2抑制剂用于治疗癌症的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694677A2 (en) * | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| CN104768555B (zh) * | 2012-04-13 | 2018-10-30 | Epizyme股份有限公司 | 用于治疗癌症的联合治疗 |
| MX376008B (es) * | 2012-10-15 | 2025-03-07 | Epizyme Inc | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. |
| WO2014092905A1 (en) * | 2012-12-10 | 2014-06-19 | Children's Medical Center Corporation | Methods and assays for combination treatment of cancer |
| WO2015103431A1 (en) * | 2013-12-31 | 2015-07-09 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced smarca4 gene expression or protein function |
| BR112017004459A2 (pt) * | 2014-09-05 | 2017-12-05 | Arqule Inc | composições e métodos para o tratamento de distúrbios de proliferação |
| AU2016325643B2 (en) * | 2015-09-25 | 2022-07-21 | Epizyme, Inc. | Method of treating malignant rhabdoid tumor or small cell cancer of the ovary of the hypercalcemic type |
| WO2017139404A1 (en) * | 2016-02-08 | 2017-08-17 | Epizyme, Inc. | Methods of treating cancer |
| WO2017214373A1 (en) * | 2016-06-08 | 2017-12-14 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
-
2018
- 2018-02-02 EP EP18748404.3A patent/EP3576729A4/en not_active Withdrawn
- 2018-02-02 CN CN201880014459.3A patent/CN110366413A/zh active Pending
- 2018-02-02 AU AU2018217139A patent/AU2018217139A1/en not_active Abandoned
- 2018-02-02 WO PCT/US2018/016562 patent/WO2018144798A1/en not_active Ceased
- 2018-02-02 JP JP2019541403A patent/JP7324144B2/ja active Active
- 2018-02-02 US US16/482,748 patent/US20190350929A1/en not_active Abandoned
-
2021
- 2021-11-18 US US17/529,609 patent/US20220175771A1/en not_active Abandoned
-
2022
- 2022-12-27 JP JP2022210528A patent/JP2023026523A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505426A5 (enExample) | ||
| Ng et al. | Antibodies against endogenous retroviruses promote lung cancer immunotherapy | |
| Genova et al. | Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade | |
| Martini et al. | Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events | |
| Hodi et al. | TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma | |
| Herbst et al. | The biology and management of non-small cell lung cancer | |
| Formenti et al. | Radiotherapy induces responses of lung cancer to CTLA-4 blockade | |
| Herbst et al. | Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC | |
| Karimkhani et al. | A review of novel therapies for melanoma | |
| WO2018223040A1 (en) | Methods of treating a tumor using an anti-pd-1 antibody | |
| US20240125787A1 (en) | Sting levels as a biomarker for cancer immunotherapy | |
| Ali et al. | PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer | |
| Visser et al. | Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study | |
| Bai et al. | PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs | |
| Byeon et al. | Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment | |
| Brizzi et al. | Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs? | |
| Xue et al. | Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy | |
| Algazi et al. | Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma | |
| Lazzari et al. | Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors | |
| Hu et al. | Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations | |
| Lazzari et al. | Second-line therapy of squamous non-small cell lung cancer: an evolving landscape | |
| Han et al. | Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma | |
| Mourah et al. | Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma | |
| Chen et al. | Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan | |
| Moniz et al. | A prospective cohort study of biomarkers in squamous cell carcinoma of the anal canal (SCCAC) and their influence on treatment outcomes |